Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity

Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic in...

Full description

Bibliographic Details
Main Authors: David P. Sparling, Junjie Yu, KyeongJin Kim, Changyu Zhu, Sebastian Brachs, Andreas L. Birkenfeld, Utpal B. Pajvani
Format: Article
Language:English
Published: Elsevier 2016-02-01
Series:Molecular Metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877815002185
id doaj-5cd97b3acb34442aa129a27401d92fbc
record_format Article
spelling doaj-5cd97b3acb34442aa129a27401d92fbc2020-11-24T21:22:20ZengElsevierMolecular Metabolism2212-87782016-02-0152113121Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivityDavid P. Sparling0Junjie Yu1KyeongJin Kim2Changyu Zhu3Sebastian Brachs4Andreas L. Birkenfeld5Utpal B. Pajvani6Departments of Pediatrics, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Medicine, Columbia University, New York, NY 10032, USADepartment of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité – University School of Medicine, Berlin, GermanySection of Metabolic Vascular Medicine, Medical Clinic III and Paul Langerhans Institute Dresden (PLID), a member of the German Center for Diabetes Research (DZD), Technische Universität Dresden, Germany; Section of Diabetes and Nutritional Sciences, Rayne Institute, Denmark Hill Campus, King's College London, UKDepartment of Medicine, Columbia University, New York, NY 10032, USA; Corresponding author. 1150 St. Nicholas Avenue, Room 313A, Columbia University, New York, NY 10032, USA. Tel.: +1 212 851 4886; fax: +1 212 851 4810.Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic insulin resistance, opening up therapeutic avenues for Notch inhibitors to be repurposed for T2D. Herein, we tested the systemic effects of γ-secretase inhibitors (GSIs), which prevent endogenous Notch activation, and confirmed these effects through creation and characterization of two different adipocyte-specific Notch loss-of-function mouse models through genetic ablation of the Notch transcriptional effector Rbp-Jk (A-Rbpj) and the obligate γ-secretase component Nicastrin (A-Nicastrin). Methods: Glucose homeostasis and both local adipose and systemic insulin sensitivity were examined in GSI-treated, A-Rbpj and A-Nicastrin mice, as well as vehicle-treated or control littermates, with complementary in vitro studies in primary hepatocytes and 3T3-L1 adipocytes. Results: GSI-treatment increases hepatic insulin sensitivity in obese mice but leads to reciprocal lowering of adipose glucose disposal. While A-Rbpj mice show normal body weight, adipose development and mass and unchanged adipose insulin sensitivity as control littermates, A-Nicastrin mice are relatively insulin-resistant, mirroring the GSI effect on adipose insulin action. Conclusions: Notch signaling is dispensable for normal adipocyte function, but adipocyte-specific γ-secretase blockade reduces adipose insulin sensitivity, suggesting that specific Notch inhibitors would be preferable to GSIs for application in T2D. Keywords: Notch, γ-secretase complex, Insulin resistancehttp://www.sciencedirect.com/science/article/pii/S2212877815002185
collection DOAJ
language English
format Article
sources DOAJ
author David P. Sparling
Junjie Yu
KyeongJin Kim
Changyu Zhu
Sebastian Brachs
Andreas L. Birkenfeld
Utpal B. Pajvani
spellingShingle David P. Sparling
Junjie Yu
KyeongJin Kim
Changyu Zhu
Sebastian Brachs
Andreas L. Birkenfeld
Utpal B. Pajvani
Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
Molecular Metabolism
author_facet David P. Sparling
Junjie Yu
KyeongJin Kim
Changyu Zhu
Sebastian Brachs
Andreas L. Birkenfeld
Utpal B. Pajvani
author_sort David P. Sparling
title Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
title_short Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
title_full Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
title_fullStr Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
title_full_unstemmed Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity
title_sort adipocyte-specific blockade of gamma-secretase, but not inhibition of notch activity, reduces adipose insulin sensitivity
publisher Elsevier
series Molecular Metabolism
issn 2212-8778
publishDate 2016-02-01
description Objective: As the obesity pandemic continues to expand, novel molecular targets to reduce obesity-related insulin resistance and Type 2 Diabetes (T2D) continue to be needed. We have recently shown that obesity is associated with reactivated liver Notch signaling, which, in turn, increases hepatic insulin resistance, opening up therapeutic avenues for Notch inhibitors to be repurposed for T2D. Herein, we tested the systemic effects of γ-secretase inhibitors (GSIs), which prevent endogenous Notch activation, and confirmed these effects through creation and characterization of two different adipocyte-specific Notch loss-of-function mouse models through genetic ablation of the Notch transcriptional effector Rbp-Jk (A-Rbpj) and the obligate γ-secretase component Nicastrin (A-Nicastrin). Methods: Glucose homeostasis and both local adipose and systemic insulin sensitivity were examined in GSI-treated, A-Rbpj and A-Nicastrin mice, as well as vehicle-treated or control littermates, with complementary in vitro studies in primary hepatocytes and 3T3-L1 adipocytes. Results: GSI-treatment increases hepatic insulin sensitivity in obese mice but leads to reciprocal lowering of adipose glucose disposal. While A-Rbpj mice show normal body weight, adipose development and mass and unchanged adipose insulin sensitivity as control littermates, A-Nicastrin mice are relatively insulin-resistant, mirroring the GSI effect on adipose insulin action. Conclusions: Notch signaling is dispensable for normal adipocyte function, but adipocyte-specific γ-secretase blockade reduces adipose insulin sensitivity, suggesting that specific Notch inhibitors would be preferable to GSIs for application in T2D. Keywords: Notch, γ-secretase complex, Insulin resistance
url http://www.sciencedirect.com/science/article/pii/S2212877815002185
work_keys_str_mv AT davidpsparling adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT junjieyu adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT kyeongjinkim adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT changyuzhu adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT sebastianbrachs adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT andreaslbirkenfeld adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
AT utpalbpajvani adipocytespecificblockadeofgammasecretasebutnotinhibitionofnotchactivityreducesadiposeinsulinsensitivity
_version_ 1725996302641135616